NHI Reports Q2 2026 Results: Net Income Up 45.6%, Raises Dividend, Issues Strong Full-Year Guidance
NHI is trading near its 52-week low of $67.94 (9.1% above the low).
Summary
NHI's Q2 earnings beat expectations with net income up 45.6% to $1.15 per share, boosted by property sale gains and SHOP growth. The company closed its $560M NHC portfolio sale, issued robust full-year guidance, and raised its dividend.
Key Events · Earnings and Guidance · NHI
-
Q2 Earnings Beat
Net income per diluted share rose 45.6% to $1.15, including a $22M gain on property dispositions. NAREIT FFO was $1.19 per share, flat year-over-year but ahead of normalized expectations.
-
NHC Portfolio Sale Closed
The $560M sale of 35 properties to NHC closed July 1, generating an expected gain of ~$541.6M. Proceeds will fund a $127M pipeline of new investments via a 1031 exchange.
-
Full-Year Guidance Raised
2026 net income guidance of $703M-$705M reflects the NHC sale gain; normalized FFO guidance of $4.74-$4.79 per share implies steady operational growth. Assumes $180M in new investments.
-
Dividend Increased
Quarterly dividend raised to $0.94 per share from $0.92, payable November 6 to shareholders of record September 30.
Analysis · NHI · Real Estate & Construction
National Health Investors delivered a strong second quarter, with net income per share jumping 45.6% to $1.15, driven by a $22M gain on property sales and a 188% surge in SHOP NOI from recent acquisitions. The company completed the landmark $560M NHC portfolio sale on July 1, slashing leverage to 4.1x and providing ample dry powder for a $127M pipeline of new investments. Full-year guidance implies net income of $703M-$705M, largely reflecting the $541.6M expected gain on the NHC sale, while normalized FFO guidance of $4.74-$4.79 per share signals steady operational performance. The board also raised the quarterly dividend to $0.94, underscoring confidence in cash flow durability.
At the time of this filing, NHI was trading at $74.15 on NYSE in the Real Estate & Construction sector, with a market capitalization of approximately $3.6B. The 52-week trading range was $67.94 to $91.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.